Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology. 2008;134:1715–28.

Article  PubMed  Google Scholar 

Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol. 2021;56:593–619.

Article  PubMed  PubMed Central  Google Scholar 

Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725–49.

Article  PubMed  Google Scholar 

Yoshida H, Shimizu T, Yoshioka M, Taniai N. Management of portal hypertension based on portal hemodynamics. Hepatol Res. 2021;51:251–62.

Article  PubMed  Google Scholar 

Enomoto H, Ueno Y, Hiasa Y, et al. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol. 2021;56:158–67.

Article  CAS  PubMed  Google Scholar 

Atsukawa M, Tsubota A, Toyoda H, et al. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther. 2019;49:1230–41.

Article  CAS  PubMed  Google Scholar 

Nozaki A, Atsukawa M, Kondo C, et al. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int. 2020;14:225–38.

Article  PubMed  Google Scholar 

Itokawa N, Atsukawa M, Tsubota A, et al. Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: a multicenter study. Hepatol Res. 2019;49:125–35.

Article  CAS  PubMed  Google Scholar 

Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87–95.

Article  CAS  PubMed  Google Scholar 

El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154:2111–21.

Article  CAS  PubMed  Google Scholar 

Atsukawa M, Tsubota A, Kondo C, et al. Real-world clinical application of 12-week sofosbuvir/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study. Infect Dis Ther. 2020;9:851–66.

Article  PubMed  PubMed Central  Google Scholar 

Atsukawa M, Tsubota A, Kondo C, et al. Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res. 2022;52:235–46.

Article  CAS  PubMed  Google Scholar 

Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021;56:67–77.

Article  CAS  PubMed  Google Scholar 

Tahata Y, Hikita H, Mochida S, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022;57:120–32.

Article  CAS  PubMed  Google Scholar 

Sano T, Amano K, Ide T, et al. A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res. 2023;53:26–34.

Article  CAS  PubMed  Google Scholar 

Kumada T, Toyoda H, Yasuda S, et al. Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus. Infect Dis Ther. 2021;10:1001–13.

Article  PubMed  PubMed Central  Google Scholar 

Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692–9.

Article  PubMed  Google Scholar 

Lens S, Alvarado-Tapias E, Mariño Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology. 2017;153:1273–83.

Article  CAS  PubMed  Google Scholar 

Nagaoki Y, Imamura M, Teraoka Y, et al. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res. 2020;50:1222–33.

Article  CAS  PubMed  Google Scholar 

Puigvehí M, Londoño MC, Torras X, et al. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. J Gastroenterol. 2020;55:205–16.

Article  PubMed  Google Scholar 

Tajiri T, Yoshida H, Obara K, et al. General rules for recording endoscopic findings of esophagogastric varices. Dig Endosc. 2010;22:1–9.

Article  PubMed  Google Scholar 

Okaniwa S, Hirai T, Ogawa M, et al. Manual for abdominal ultrasound in cancer screening and health checkups. J Med Ultrason. 2023;50:5–49.

Article  Google Scholar 

Pfisterer N, Schwarz M, Jachs M, et al. Endoscopic band ligation is safe despite low platelet count and high INR. Hepatol Int. (in press)

Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35.

Article  PubMed  Google Scholar 

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. European Association for the Study of the Liver. J Hepatol. 2018;69:406–60.

Google Scholar 

Merkel C, Bolognesi M, Berzigotti A, et al. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. J Hepatol. 2010;52:45–53.

Article  PubMed  Google Scholar 

Allaire M, Campion B, Demory A, et al. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023;58:346–56.

Article  CAS  PubMed  Google Scholar 

de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959–74.

Article  PubMed  Google Scholar